<< Back to MOTIFvations Blog Home Page

Measuring Ras-GTP: A Critical Readout for Next-Generation RAS Therapeutics

By Nivanka Paranavitana, MS, MBA

Jun 18, 2026

Tweet

Why Measuring Active RAS Matters More Than Ever in Oncology Drug Discovery

For decades, RAS was considered one of the most elusive targets in oncology. Long labeled "undruggable," mutant RAS proteins drive some of the most aggressive cancers, including pancreatic, colorectal, and non-small cell lung cancers. Today, that narrative has changed dramatically.

The field is experiencing a wave of innovation focused on directly targeting RAS signaling, particularly the active, GTP-bound ("ON") state responsible for driving oncogenic activity. As RAS-targeted pipelines continue to mature, the ability to accurately measure active Ras-GTP is becoming increasingly important across drug discovery and translational research.

 Back to Table of Contents

The Shift Toward Active-State RAS Inhibition

Early KRAS inhibitors primarily targeted the inactive, GDP-bound form of the protein. More recently, a new generation of RAS(ON) inhibitors has emerged, designed to engage active Ras-GTP directly and achieve deeper pathway suppression.

This evolution is reflected in the development of tri-complex inhibitors and molecular glue approaches that selectively target active RAS signaling. Companies such as Revolution Medicines are helping advance this paradigm through programs targeting active RAS across multiple mutations.

As more therapeutic candidates are designed to interact with active RAS signaling, direct measurement of Ras-GTP is becoming a critical component of preclinical and translational evaluation.

 Back to Table of Contents

Ras-GTP as a Critical Pharmacodynamic Readout

A central question in RAS drug development is straightforward: Does the therapy suppress active RAS signaling?

Answering this question is essential across hit identification, lead optimization, translational validation, resistance modeling, and combination therapy studies.

Ras activation assays provide a direct biochemical measure of pathway activity by quantifying the active, GTP-bound form of RAS. This information complements downstream biomarkers such as phospho-ERK and phospho-MEK, which may not fully capture pathway reactivation, compensatory signaling, or incomplete target suppression.

As a result, Ras-GTP measurements are increasingly incorporated into integrated pharmacodynamic workflows designed to assess therapeutic efficacy and target engagement.

 Back to Table of Contents

Resistance Is Driving Renewed Interest in Active-State Monitoring

Acquired resistance remains one of the most significant challenges facing RAS-targeted therapies. Tumors frequently restore signaling through activation of upstream pathways or alternative RAS isoforms, leading to renewed accumulation of active Ras-GTP despite treatment.

To address these mechanisms, developers are expanding into pan-RAS inhibitors and rational combination strategies involving SHP2, SOS1, EGFR, and MAPK pathway targets. Companies such as Erasca are pursuing novel approaches designed to suppress both mutant and wild-type RAS signaling.

These next-generation strategies increase the need for assays capable of measuring pathway suppression across multiple signaling contexts and biological models.

 Back to Table of Contents

Expanding Beyond KRAS G12C

While early breakthroughs focused heavily on KRAS G12C, the field is rapidly advancing toward additional oncogenic variants, including KRAS G12D and KRAS G12V, which are highly prevalent in pancreatic and colorectal cancers.

Organizations such as Amgen and AstraZeneca continue to expand development efforts across multiple KRAS mutations and therapeutic modalities.

Because these variants can exhibit distinct biochemical and signaling properties, direct measurement of Ras-GTP remains an important tool for compound characterization, potency assessment, and comparative pathway analysis.

 Back to Table of Contents

The Growing Strategic Role of Ras Activation Assays

The resurgence of RAS biology has transformed Ras activation assays from specialized signaling tools into critical components of modern oncology research workflows.

Researchers increasingly rely on these assays to:

• Quantify active Ras-GTP levels
• Monitor pharmacodynamic response
• Evaluate resistance mechanisms
• Validate pathway suppression
• Benchmark combination therapies
• Compare signaling across RAS variants

The future of RAS drug discovery is no longer focused on whether RAS can be targeted. The challenge now is understanding when, where, and how active RAS signaling is truly being suppressed.

As RAS-directed therapies continue to evolve, sensitive and reproducible Ras-GTP measurements remain essential for translating biological insight into therapeutic progress.

 Back to Table of Contents

About Active Motif

Active Motif provides research tools that support signaling pathway analysis and translational drug discovery. Our portfolio of RAS research solutions enables direct measurement of active, GTP-bound RAS and supports studies of pathway activation, target engagement, and therapeutic response.

Our offerings include Ras Activation Assays, such as the Ras GTPase Chemi ELISA Kit, KRAS In-well Lysis ELISA Kit, and NRAS In-well Lysis ELISA Kit, as well as highly validated antibodies for RAS pathway research, including AbFlex^® KRAS antibody (rAb), AbFlex^® NRAS antibody (rAb), and NRAS antibody (pAb).

Together, these tools help researchers investigate RAS biology and advance the development of next-generation oncology therapeutics.

 Back to Table of Contents

About the author

Nivanka Paranavitana, MS, MBA

Originally from Sri Lanka, Nivanka moved to the United States during high school and pursued her passion for the life sciences at Indiana University Bloomington, earning a Bachelor of Arts in Biology. She subsequently received a Master of Science in Biochemistry and Molecular Biology from Indiana University School of Medicine. Her graduate research was conducted in the laboratory of Lawrence Quilliam, where she characterized Rap1a, a Ras-related small GTPase involved in cellular signaling pathways. Recognizing the importance of bridging science and business, Nivanka later earned an MBA from University of San Francisco. Over the course of her career, she has built extensive experience supporting the Bay Area's biotechnology, pharmaceutical, and academic research communities, helping scientists access innovative technologies that accelerate drug discovery and translational research. Outside of work, Nivanka enjoys exploring the outdoors, cooking, and spending quality time with her family.

Contact Stuart on LinkedIn

Related Articles

<< Back to MOTIFvations Blog Home Page